Contribute Try STAT+ Today

CAMBRIDGE, Mass. — Biopharma’s reputation is, objectively speaking, the worst.

And on Thursday, several biotech CEOs said in no uncertain terms that they believed that negative reputation was earned — particularly because of some drug pricing decisions.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • I would like to know on what basis, (facts, data, polling. etc) these three CEOs have based their views on the biotech industry’s reputation? Or are they reacting to press stories about prices on individual drugs? The Gallup study included in this story refers to “pharma,” not specifically biotech. If we don’t make the distinction you really can’t expect the public to do the same.

  • Leschly’s company Bluebird Bio sells a drug that costs $1.8 million. Yes, it’s a potential cure for a rare disease, so who knows what’s fair. But it might be worth noting that in an article where he complains about profit-taking from other unnamed firms.

Comments are closed.